Logo image of LQDA

LIQUIDIA CORP (LQDA) Stock Fundamental Analysis

NASDAQ:LQDA - Nasdaq - US53635D2027 - Common Stock - Currency: USD

13.54  -0.24 (-1.74%)

Fundamental Rating

2

Overall LQDA gets a fundamental rating of 2 out of 10. We evaluated LQDA against 195 industry peers in the Pharmaceuticals industry. LQDA may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, LQDA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LQDA had negative earnings in the past year.
LQDA had a negative operating cash flow in the past year.
LQDA had negative earnings in each of the past 5 years.
LQDA had a negative operating cash flow in each of the past 5 years.
LQDA Yearly Net Income VS EBIT VS OCF VS FCFLQDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

LQDA has a worse Return On Assets (-56.21%) than 64.10% of its industry peers.
LQDA has a Return On Equity of -257.14%. This is in the lower half of the industry: LQDA underperforms 72.82% of its industry peers.
Industry RankSector Rank
ROA -56.21%
ROE -257.14%
ROIC N/A
ROA(3y)-51.66%
ROA(5y)-50.39%
ROE(3y)-127.25%
ROE(5y)-103.75%
ROIC(3y)N/A
ROIC(5y)N/A
LQDA Yearly ROA, ROE, ROICLQDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

With a decent Gross Margin value of 58.08%, LQDA is doing good in the industry, outperforming 67.69% of the companies in the same industry.
LQDA's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for LQDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58.08%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.82%
GM growth 5Y-8.41%
LQDA Yearly Profit, Operating, Gross MarginsLQDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

3

2. Health

2.1 Basic Checks

LQDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
LQDA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for LQDA has been increased compared to 5 years ago.
Compared to 1 year ago, LQDA has a worse debt to assets ratio.
LQDA Yearly Shares OutstandingLQDA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
LQDA Yearly Total Debt VS Total AssetsLQDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

LQDA has an Altman-Z score of -0.87. This is a bad value and indicates that LQDA is not financially healthy and even has some risk of bankruptcy.
LQDA has a Altman-Z score of -0.87. This is comparable to the rest of the industry: LQDA outperforms 50.26% of its industry peers.
LQDA has a Debt/Equity ratio of 2.08. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 2.08, LQDA is not doing good in the industry: 77.44% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.08
Debt/FCF N/A
Altman-Z -0.87
ROIC/WACCN/A
WACC9.69%
LQDA Yearly LT Debt VS Equity VS FCFLQDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

2.3 Liquidity

LQDA has a Current Ratio of 2.93. This indicates that LQDA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of LQDA (2.93) is comparable to the rest of the industry.
A Quick Ratio of 2.91 indicates that LQDA has no problem at all paying its short term obligations.
With a Quick ratio value of 2.91, LQDA perfoms like the industry average, outperforming 54.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.93
Quick Ratio 2.91
LQDA Yearly Current Assets VS Current LiabilitesLQDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

LQDA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.28%.
The Revenue for LQDA has decreased by -11.45% in the past year. This is quite bad
Measured over the past years, LQDA shows a quite strong growth in Revenue. The Revenue has been growing by 11.64% on average per year.
EPS 1Y (TTM)-1.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
Revenue 1Y (TTM)-11.45%
Revenue growth 3Y2.89%
Revenue growth 5Y11.64%
Sales Q2Q%4.98%

3.2 Future

LQDA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.56% yearly.
Based on estimates for the next years, LQDA will show a very strong growth in Revenue. The Revenue will grow by 104.74% on average per year.
EPS Next Y-3.89%
EPS Next 2Y30.12%
EPS Next 3Y33.19%
EPS Next 5Y23.56%
Revenue Next Year146.53%
Revenue Next 2Y233.42%
Revenue Next 3Y169.86%
Revenue Next 5Y104.74%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LQDA Yearly Revenue VS EstimatesLQDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
LQDA Yearly EPS VS EstimatesLQDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LQDA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LQDA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LQDA Price Earnings VS Forward Price EarningsLQDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LQDA Per share dataLQDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as LQDA's earnings are expected to grow with 33.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.12%
EPS Next 3Y33.19%

More info and screens

0

5. Dividend

5.1 Amount

LQDA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIQUIDIA CORP

NASDAQ:LQDA (6/25/2025, 2:08:09 PM)

13.54

-0.24 (-1.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-05 2025-08-05/amc
Inst Owners63.22%
Inst Owner Change2.6%
Ins Owners3.74%
Ins Owner Change3.89%
Market Cap1.16B
Analysts82.5
Price Target31.42 (132.05%)
Short Float %23.03%
Short Ratio7.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.71%
Min EPS beat(2)-20.44%
Max EPS beat(2)-10.99%
EPS beat(4)1
Avg EPS beat(4)-4.06%
Min EPS beat(4)-20.44%
Max EPS beat(4)21.21%
EPS beat(8)1
Avg EPS beat(8)-35.5%
EPS beat(12)4
Avg EPS beat(12)-16.3%
EPS beat(16)5
Avg EPS beat(16)-21.05%
Revenue beat(2)0
Avg Revenue beat(2)-22.07%
Min Revenue beat(2)-37.8%
Max Revenue beat(2)-6.33%
Revenue beat(4)1
Avg Revenue beat(4)-25.52%
Min Revenue beat(4)-62.04%
Max Revenue beat(4)4.12%
Revenue beat(8)2
Avg Revenue beat(8)-19.09%
Revenue beat(12)5
Avg Revenue beat(12)-8.64%
Revenue beat(16)9
Avg Revenue beat(16)0.92%
PT rev (1m)15.02%
PT rev (3m)21.58%
EPS NQ rev (1m)-6.18%
EPS NQ rev (3m)-11.03%
EPS NY rev (1m)-7.93%
EPS NY rev (3m)-16.99%
Revenue NQ rev (1m)-13.89%
Revenue NQ rev (3m)-43.87%
Revenue NY rev (1m)-12.1%
Revenue NY rev (3m)-20.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 81.83
P/FCF N/A
P/OCF N/A
P/B 23.28
P/tB 27.1
EV/EBITDA N/A
EPS(TTM)-1.58
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-1.26
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS0.17
BVpS0.58
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -56.21%
ROE -257.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 58.08%
FCFM N/A
ROA(3y)-51.66%
ROA(5y)-50.39%
ROE(3y)-127.25%
ROE(5y)-103.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.82%
GM growth 5Y-8.41%
F-Score1
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 2.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 377.72%
Cap/Sales 57.66%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.93
Quick Ratio 2.91
Altman-Z -0.87
F-Score1
WACC9.69%
ROIC/WACCN/A
Cap/Depr(3y)306.37%
Cap/Depr(5y)189%
Cap/Sales(3y)42.88%
Cap/Sales(5y)46.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
EPS Next Y-3.89%
EPS Next 2Y30.12%
EPS Next 3Y33.19%
EPS Next 5Y23.56%
Revenue 1Y (TTM)-11.45%
Revenue growth 3Y2.89%
Revenue growth 5Y11.64%
Sales Q2Q%4.98%
Revenue Next Year146.53%
Revenue Next 2Y233.42%
Revenue Next 3Y169.86%
Revenue Next 5Y104.74%
EBIT growth 1Y-37.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.43%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-280.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-263.9%
OCF growth 3YN/A
OCF growth 5YN/A